SV

Street Verdict

Analyst Scorecard

SYMBIOTEC · NSE

Symbiotec Pharmalab Limited

₹1,598.6

-0.39% (-₹6.2)

Prev. close

₹1,604.8

Volume

2,94,589

Delivery %

37.8%

As of

20 Nov 2026

Price history

₹1,598.6+₹500.9 (+45.63%) · 3M
01 Sept 2026 → 20 Nov 2026
1,1001,2001,3001,4001,5001,60001 Sept22 Sept13 Oct02 Nov20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

none in range

Long-Horizon

1 · 1 bull / 0 neutral / 0 bear

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

No trackable analyst calls on Symbiotec Pharmalab Limited yet.

Long-Horizon calls · 1yr+ horizon · verdict pending

CallAnalystInstrumentVerdictActions

Fundamentals

About Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited develops, manufactures, and markets active pharmaceutical ingredients (APIs) in India. The company provides cortico-steroid and hormone (Steroid) APIs; nutraceuticals; and other services. The company was founded in 1995 and is based in Indore, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Mr. Anil Satwani

Headquarters

Indore

Employees

1,915

Key stats

Market cap

₹6,718.62 Cr

P/E ratio (TTM)

84.3

Dividend yield

0.00%

EPS (TTM)

₹14.63

Shares float

2.54 Cr

EPS · quarter ended Jun 2026

₹2.19

Financial Performance

01 · Financials

0 Cr250 Cr500 Cr750 Cr1000 Cr₹0%5%10%15%FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

05101520₹FY23FY24FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-50%0%50%100%FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹0×0.25×0.5×0.75×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-500 Cr0 Cr500 Cr1000 Cr₹FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY23FY24FY25FY26
₹545.78 Cr₹716.25 Cr₹751.55 Cr₹869.15 Cr
EBITDA
₹72.17 Cr₹177.04 Cr₹206.11 Cr₹231.97 Cr
₹23.47 Cr₹100.18 Cr₹96.78 Cr₹109.88 Cr
Diluted EPS
₹3.65₹15.59₹15.06₹17.1

09 · Balance Sheet

Annual

Line itemFY23FY24FY25FY26
₹989.99 Cr₹1,294.79 Cr₹1,579.65 Cr₹1,780.79 Cr
₹219.96 Cr₹250.60 Cr₹544.44 Cr₹390.99 Cr
Stockholders' equity
₹621.53 Cr₹715.05 Cr₹814.89 Cr₹1,149.73 Cr

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY23FY24FY25FY26
₹69.24 Cr₹187.50 Cr₹47.26 Cr₹174.59 Cr
Investing cash flow
₹-219.99 Cr₹-206.41 Cr₹-306.52 Cr₹-226.93 Cr
₹146.14 Cr₹21.85 Cr₹278.16 Cr₹35.99 Cr
Capital expenditure
₹-224.39 Cr₹-209.77 Cr₹-308.12 Cr₹-225.72 Cr
End cash position
₹4.55 Cr₹7.50 Cr₹26.39 Cr₹10.04 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemAug 26
Promoter33.28%
Public66.72%
Employee trusts0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Symbiotec Pharmalab Limited₹6,718.62 Cr₹1,233.286.35.849.6%0.34+15.6%—

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

SYMBIOTEC

Symbiotec Pharmalab IPO Lists at ₹988 After 75.06x Demand

Multibagg AI · 1 day ago

SYMBIOTEC

Symbiotec Pharmalab: Earnings visibility for new growth engines improves

Moneycontrol.com · 4 days ago